top of page
Browse by category
Search
Zhejiang Doer Biologics completes enrolment of the Phase 1b/2a trial evaluating DR10624 in people with obesity with modest hypertriglyceridemia
Zhejiang Doer Biologics has completed the enrolment in the Phase 1b/2a trial evaluating DR10624 in people with obesity with modest...
First subject receives DR10624 for the treatment of obesity and hypertriglyceridemia
Zhejiang Doer Biologics, a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...
Browse by tag
bottom of page